Saudi Arabia Molecular Diagnostics Market (2025-2030)
The Saudi Arabia Molecular Diagnostics Market was valued at $93.2 Million in 2025 and projected to reach to $138.9 Million by 2030, representing a compound annual growth rate of 8.3%. Saudi Arabia's molecular diagnostics market is positioned for sustained growth through 2030, supported by government healthcare reforms and increased private sector participation.
Saudi Arabia Molecular Diagnostics Market Trends and Insights
- This growth trajectory reflects Saudi Arabia's increasing investment in advanced healthcare infrastructure and diagnostic capabilities as part of its Vision 2030 modernization agenda.
- The market in Saudi Arabia is driven by rising prevalence of chronic diseases, growing demand for precision medicine, and enhanced government support for healthcare innovation. The molecular diagnostics sector in Saudi Arabia is benefiting from improved laboratory standards, increased adoption of PCR and sequencing technologies, and expanding private healthcare networks.
- Saudi Arabia's strategic focus on reducing dependency on imported medical services is accelerating local diagnostic capacity development.
- Between 2025 and 2030, Saudi Arabia is expected to see significant investments in genomic testing, infectious disease diagnostics, and cancer screening applications, positioning the country as a regional hub for molecular diagnostics excellence..
Key Market Statistics
- CAGR (2025-2030) 8.3% CAGR
- Market Size, 2025 ~USD 93.2 Million
- Forecast, 2030 ~USD 138.9 Million
- Country Saudi Arabia
Saudi Arabia Molecular Diagnostics Market Overview
Vision 2030 Healthcare Investment :
Saudi Arabia's molecular diagnostics market is expanding rapidly as part of the Kingdom's Vision 2030 initiative, which prioritizes advanced healthcare infrastructure and diagnostic modernization across the nation.
Market Valuation Growth :
The market is valued at $93.2 million in 2025 and is projected to reach $138.9 million by 2030, representing a robust 8.3% CAGR driven by increased healthcare spending and diagnostic adoption.
Rising Disease Prevalence :
Growing prevalence of chronic diseases, genetic disorders, and infectious diseases in Saudi Arabia is driving demand for advanced molecular diagnostic solutions and personalized medicine approaches.
Healthcare Infrastructure Development :
Significant investments in hospital modernization, diagnostic centers, and laboratory automation across major cities like Riyadh and Jeddah are accelerating the adoption of molecular diagnostics technologies.
Saudi Arabia Molecular Diagnostics Market Dynamics
- The Kingdom's commitment to reducing disease burden and improving diagnostic accuracy aligns with global standards, creating opportunities for advanced testing platforms and personalized medicine solutions.
- Healthcare providers are increasingly adopting molecular diagnostics for cancer screening, infectious disease detection, and genetic testing, driven by rising patient awareness and physician recommendations. The competitive landscape is evolving with both international diagnostic companies and local healthcare providers expanding their molecular testing capabilities.
- Government initiatives promoting preventive healthcare and early disease detection are expected to further accelerate market penetration.
- Investment in laboratory infrastructure, skilled workforce development, and regulatory framework improvements will continue to support market expansion through the forecast period..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Saudi Arabia's molecular diagnostics market is valued at $93.2 million in 2025 and will grow to $138.9 million by 2030, representing an 8.3% CAGR.
- Saudi Arabia is leveraging Vision 2030 initiatives to build domestic diagnostic capabilities and reduce reliance on imported medical services.
- Growth in Saudi Arabia is fueled by rising chronic disease prevalence, precision medicine adoption, and government healthcare modernization investments.
- Saudi Arabia is emerging as a regional leader in genomic testing, infectious disease diagnostics, and cancer screening technologies.
Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HEPATITIS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | LAB TESTS (Test Type) |
| Market Size Base Year (Billions) | ~USD 19.44 (2025) |
| Revenue Forecast (Billions) | ~USD 30.74 (2030) |
| Segments Covered | Product & Service, Test Type, Sample Type, Type |
Saudi Arabia Molecular Diagnostics Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Kits
- Services & Software
By Test Type
- Lab Tests
- Poc Tests
By Sample Type
- Blood, Serum & Plasma
- Other Sample Types
- Urine
By Type
- Breast Cancer
- Colorectal Cancer
- Influenza
- Lung Cancer
- Other Cancers
- Other Respiratory Infectious Diseases
- Pharyngitis
- Prostate Cancer
- Tuberculosis
Target Audience
- Diagnostic Equipment Manufacturers : Need market-specific data to assess demand for molecular diagnostic platforms, plan product localization, and identify distribution partnerships in Saudi Arabia's growing healthcare sector.
- Healthcare Providers & Hospital Networks : Require market insights to justify investments in molecular diagnostics infrastructure, benchmark against regional peers, and align service expansion with Vision 2030 healthcare objectives.
- Private Equity & Investment Firms : Seek validated market data and growth projections for Saudi Arabia to evaluate investment opportunities in diagnostic companies, laboratory networks, and healthcare technology ventures.
- Pharmaceutical & Biotech Companies : Need market intelligence on molecular diagnostics adoption rates and disease prevalence in Saudi Arabia to support companion diagnostics development and precision medicine commercialization strategies.
- Healthcare Consultants & Advisors : Require country-specific market analysis and forecasts to provide credible strategic recommendations to clients entering or expanding in Saudi Arabia's molecular diagnostics sector.
Key Companies in the Saudi Arabia Molecular Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease and HAIs),Virology, oncology, and genetics assays, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, logistics, O&M, mission-critical facilities), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CODEXIS, INC. | United States | Public Company | CodeEvolver-enabled enzyme products and services,ECO Synthesis RNAi manufacturing platform (licenses, milestones, royalties),Other technology partnerships and R&D collaborations, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging,Pathology and centres of excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array instruments and consumables, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, treatment support),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| BIOMÉRIEUX | France | Public Company | |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices (cardiovascular, diabetes care, neuromodulation),Diagnostic Products (lab, molecular, point-of-care, rapid),Nutritional Products (pediatric, adult, infant formula), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant/viral load assays),Oncology and sexual and reproductive health assays, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, autoimmune),Life science reagents and assay platforms,Instruments, software, and services, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
CEPHEID INC.
Cepheid Inc. is a private U.S. diagnostic company founded in 1996 with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing solutions.
FLUOR CORPORATION
Fluor Corporation is a large U.S. engineering and construction company founded in 1912, operating as a public company with approximately 23,000 employees. The firm provides design, engineering, procurement, and construction services across multiple industries.
SANOFI
Sanofi is a major French pharmaceutical company founded in 1994 and publicly traded, with over 74,800 employees worldwide. The company develops and manufactures prescription medicines, vaccines, and consumer healthcare products.
CODEXIS, INC.
Codexis, Inc. is a publicly traded U.S. biotechnology company founded in 2002 with 146 employees. The company develops and commercializes biocatalysts and enzymes for pharmaceutical and chemical manufacturing.
UNILABS
Unilabs is a private Swiss clinical laboratory and diagnostics company founded in 1987 with 1,897 employees. The company offers laboratory testing and diagnostic services across Europe.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a publicly traded Japanese chemical and diagnostics company founded in 1939 with 696 employees. The company manufactures diagnostic reagents, pharmaceuticals, and chemical products.
DANAHER CORPORATION
Danaher Corporation is a large publicly traded U.S. conglomerate founded in 1969 with 59,000 employees. The company operates across multiple sectors including diagnostics, life sciences, and environmental solutions.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded U.S. genomics company founded in 1998 with 8,625 employees. The company designs and manufactures DNA sequencing and array-based analysis systems.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. medical device company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and surgical products focused on women's health and oncology.
BIOMÉRIEUX
bioMérieux is a publicly traded French diagnostics company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and food safety.
ABBOTT LABORATORIES
Abbott Laboratories is a large publicly traded U.S. healthcare company founded in 1888 with 115,000 employees. The company manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a major publicly traded U.S. life sciences company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, software, and services for research and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a publicly traded Dutch life sciences company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. life sciences and diagnostics company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a publicly traded Spanish pharmaceutical and diagnostics company founded in 1909 with 25,000 employees. The company specializes in plasma-derived medicines, transfusion medicine, and diagnostics.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise valuation data for Saudi Arabia's molecular diagnostics market with verified CAGR of 8.3%, enabling accurate financial forecasting and investment decision-making for the 2025-2030 period.
- Vision 2030 Alignment Strategy : Understand how Saudi Arabia's healthcare modernization agenda directly impacts molecular diagnostics adoption, helping businesses align product offerings and market entry strategies with government priorities.
- Competitive Landscape Intelligence : Gain insights into market dynamics specific to Saudi Arabia, including key drivers, barriers to entry, and competitive positioning to develop targeted go-to-market strategies for the Kingdom.
- Investment & Partnership Opportunities : Identify high-potential segments and geographic hotspots within Saudi Arabia for partnerships, joint ventures, and expansion initiatives in molecular diagnostics and laboratory services.
- Regulatory & Infrastructure Insights : Access detailed information on Saudi Arabia's healthcare infrastructure development, regulatory environment, and reimbursement landscape to mitigate risks and optimize market entry strategies.
Frequently asked questions
What is the current size of Saudi Arabia's molecular diagnostics market?
Saudi Arabia's molecular diagnostics market is valued at $93.2 million in 2025 and is projected to reach $138.9 million by 2030.
What is the expected growth rate for molecular diagnostics in Saudi Arabia?
Saudi Arabia's molecular diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2030.
What factors are driving growth in Saudi Arabia's molecular diagnostics market?
Growth in Saudi Arabia is driven by Vision 2030 healthcare modernization, rising chronic disease prevalence, increased precision medicine adoption, and government investments in diagnostic infrastructure.
Which diagnostic technologies are gaining traction in Saudi Arabia?
Saudi Arabia is seeing increased adoption of PCR technologies, genomic sequencing, infectious disease diagnostics, and cancer screening applications.
How is Saudi Arabia positioning itself in the regional molecular diagnostics landscape?
Saudi Arabia is strategically developing local diagnostic capacity through government support and private sector expansion to become a regional hub for molecular diagnostics and reduce dependency on imported medical services.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown Of Primary Participants
Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:
Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region
Get the Full Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Molecular Diagnostics Market.
- Canada Molecular Diagnostics Market
- US Molecular Diagnostics Market
- Germany Molecular Diagnostics Market
- UK Molecular Diagnostics Market
- France Molecular Diagnostics Market
- Italy Molecular Diagnostics Market
- Spain Molecular Diagnostics Market
- Russia Molecular Diagnostics Market
- Switzerland Molecular Diagnostics Market
- China Molecular Diagnostics Market
- Japan Molecular Diagnostics Market
- India Molecular Diagnostics Market
- Australia Molecular Diagnostics Market
- South Korea Molecular Diagnostics Market
- Brazil Molecular Diagnostics Market
- Mexico Molecular Diagnostics Market
- UAE Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report